| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Larixyl acetate targets the TRPC6 (transient receptor potential canonical 6) channel, a non-selective cation channel involved in calcium signaling. It inhibits TRPC6 with an IC₅₀ of 0.1-0.6 µM and shows selectivity over TRPC3 (12-fold) and TRPC7 (5-fold). TRPC6 is involved in various physiological processes including smooth muscle contraction, neuronal signaling, and endothelial function. By inhibiting TRPC6, Larixyl acetate modulates calcium influx and downstream signaling pathways. It may also affect membrane fusion processes in viral entry.
|
|---|---|
| ln Vitro |
Larixyl acetate inhibits TRPC6 channel activity with an IC₅₀ of 0.1-0.6 µM in electrophysiological and calcium imaging assays. It shows 12-fold selectivity over TRPC3 and 5-fold selectivity over TRPC7. The compound prevents HPV infection and protects against traumatic brain injury-induced systemic endothelial dysfunction. These activities suggest broad potential in studying calcium signaling, viral entry, and vascular function.
|
| ln Vivo |
In vivo activity data for Larixyl acetate indicate protective effects against traumatic brain injury-induced systemic endothelial dysfunction. The compound has also been shown to have antiviral activity against HPV. These in vivo effects are likely mediated through TRPC6 inhibition and modulation of calcium signaling, as well as effects on membrane fusion processes. However, detailed in vivo efficacy data are limited.
|
| Enzyme Assay |
The non-cellular enzyme/receptor binding assay for Larixyl acetate typically involves TRPC6 channel inhibition studies using electrophysiological techniques such as patch-clamp recordings in cells overexpressing TRPC6 channels. Alternatively, calcium flux assays using fluorescent calcium indicators (e.g., Fura-2, Fluo-4) can be employed to measure TRPC6-mediated calcium influx in the presence of the compound. IC₅₀ values are calculated from dose-response curves. Selectivity over TRPC3 and TRPC7 is assessed similarly.
|
| Cell Assay |
In vitro cellular assays for Larixyl acetate typically use cell lines expressing TRPC6 channels to evaluate channel inhibition. Cells are loaded with calcium-sensitive dyes and treated with various concentrations of the compound. TRPC6-mediated calcium influx is stimulated by agonists such as OAG (1-oleoyl-2-acetyl-sn-glycerol) or by store depletion. Fluorescence intensity is measured using a plate reader or fluorescence microscope. IC₅₀ values are calculated from dose-response curves. Antiviral activity against HPV can be assessed using HPV infection models.
|
| Animal Protocol |
In vivo animal studies for Larixyl acetate have demonstrated protective effects in traumatic brain injury models. Typical study designs involve inducing traumatic brain injury in rodents, followed by administration of Larixyl acetate via appropriate routes. Endothelial function is assessed by measuring vascular reactivity, and markers of endothelial dysfunction are analyzed. Antiviral efficacy against HPV may be evaluated in appropriate animal models. Detailed protocols are not extensively documented.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Larixyl acetate are not extensively characterized. As a diterpenoid ester with high lipophilicity (logP estimated ~5-6), it is expected to have good membrane permeability but poor aqueous solubility. The compound is almost insoluble in water (0.014 g/L at 25°C). Metabolic pathways likely involve ester hydrolysis and hepatic oxidation. Specific PK parameters such as half-life, bioavailability, and protein binding are not well documented.
|
| Toxicity/Toxicokinetics |
Toxicological data for Larixyl acetate are limited. As a naturally occurring diterpenoid, it is generally considered to have moderate toxicity at high doses. The compound may cause skin and eye irritation upon contact. Comprehensive toxicology studies including acute and chronic toxicity, genotoxicity, and organ-specific toxicity are not available. Standard laboratory safety precautions should be observed.
|
| References |
|
| Additional Infomation |
Larixyl acetate is a research-grade natural product intended for laboratory use only. It is not approved for clinical use as a therapeutic agent. Its primary applications include studying TRPC6 channel biology and calcium signaling, investigating viral entry mechanisms and HPV infection, and exploring endothelial dysfunction and traumatic brain injury. The compound is also used in fragrance research due to its woody and balsamic aroma.
|
| Molecular Formula |
C24H38O4
|
|---|---|
| Molecular Weight |
390.55612
|
| Exact Mass |
348.266
|
| CAS # |
4608-49-5
|
| Appearance |
White to off-white solid powder
|
| Density |
1.00±0.1 g/cm3 (20ºC 760 Torr)
|
| Boiling Point |
419.3±28.0 °C
|
| Melting Point |
82ºC
|
| Index of Refraction |
1.4826 (589.3 nm, 20℃)
|
| LogP |
5.044
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~286.93 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5604 mL | 12.8021 mL | 25.6043 mL | |
| 5 mM | 0.5121 mL | 2.5604 mL | 5.1209 mL | |
| 10 mM | 0.2560 mL | 1.2802 mL | 2.5604 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
